These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 27035571)

  • 21. Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease.
    Barbagallo G; Sierra-Peña M; Nemmi F; Traon AP; Meissner WG; Rascol O; Péran P
    Mov Disord; 2016 Mar; 31(3):325-34. PubMed ID: 26676922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative susceptibility mapping of the midbrain in Parkinson's disease.
    Du G; Liu T; Lewis MM; Kong L; Wang Y; Connor J; Mailman RB; Huang X
    Mov Disord; 2016 Mar; 31(3):317-24. PubMed ID: 26362242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative Susceptibility Mapping in Parkinson's Disease.
    Langkammer C; Pirpamer L; Seiler S; Deistung A; Schweser F; Franthal S; Homayoon N; Katschnig-Winter P; Koegl-Wallner M; Pendl T; Stoegerer EM; Wenzel K; Fazekas F; Ropele S; Reichenbach JR; Schmidt R; Schwingenschuh P
    PLoS One; 2016; 11(9):e0162460. PubMed ID: 27598250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease.
    Shchepinov MS; Chou VP; Pollock E; Langston JW; Cantor CR; Molinari RJ; Manning-Boğ AB
    Toxicol Lett; 2011 Nov; 207(2):97-103. PubMed ID: 21906664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parkinson Disease: Diffusion MR Imaging to Detect Nigrostriatal Pathway Loss in a Marmoset Model Treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Hikishima K; Ando K; Yano R; Kawai K; Komaki Y; Inoue T; Itoh T; Yamada M; Momoshima S; Okano HJ; Okano H
    Radiology; 2015 May; 275(2):430-7. PubMed ID: 25602507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of neuronal loss in Parkinson's disease: a neuroanatomical-biochemical perspective.
    Hornykiewicz O
    Clin Neurol Neurosurg; 1992; 94 Suppl():S9-11. PubMed ID: 1320533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease.
    Gorell JM; Ordidge RJ; Brown GG; Deniau JC; Buderer NM; Helpern JA
    Neurology; 1995 Jun; 45(6):1138-43. PubMed ID: 7783878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
    Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
    Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
    Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
    Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
    Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
    Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical MRI for iron detection in Parkinson's disease.
    Rossi M; Ruottinen H; Soimakallio S; Elovaara I; Dastidar P
    Clin Imaging; 2013; 37(4):631-6. PubMed ID: 23522789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.
    Reimão S; Pita Lobo P; Neutel D; Correia Guedes L; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    Eur J Neurol; 2015 Mar; 22(3):540-6. PubMed ID: 25534480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extra-basal ganglia iron content and non-motor symptoms in drug-naïve, early Parkinson's disease.
    Kim M; Yoo S; Kim D; Cho JW; Kim JS; Ahn JH; Mun JK; Choi I; Lee SK; Youn J
    Neurol Sci; 2021 Dec; 42(12):5297-5304. PubMed ID: 33860863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
    Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
    Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Yasuda Y; Shinagawa R; Yamada M; Mori T; Tateishi N; Fujita S
    Brain Res; 2007 Mar; 1138():196-202. PubMed ID: 17275793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Striatal shape in Parkinson's disease.
    Sterling NW; Du G; Lewis MM; Dimaio C; Kong L; Eslinger PJ; Styner M; Huang X
    Neurobiol Aging; 2013 Nov; 34(11):2510-6. PubMed ID: 23820588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.
    Iravani MM; Syed E; Jackson MJ; Johnston LC; Smith LA; Jenner P
    Eur J Neurosci; 2005 Feb; 21(4):841-54. PubMed ID: 15787691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease.
    Bergsland N; Zivadinov R; Schweser F; Hagemeier J; Lichter D; Guttuso T
    Mov Disord; 2019 Jul; 34(7):1006-1013. PubMed ID: 31180615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The expression of CYP2D22, an ortholog of human CYP2D6, in mouse striatum and its modulation in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype and nicotine-mediated neuroprotection.
    Singh S; Singh K; Patel DK; Singh C; Nath C; Singh VK; Singh RK; Singh MP
    Rejuvenation Res; 2009 Jun; 12(3):185-97. PubMed ID: 19594327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.